High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7569-7573

  Mæhle, Lovise ^a   Apold, Jaran ^d,e   Paulsen, Torbjørn ^b,c   Hagen, Bjørn ^f   Løvslett, Kjell ^g   Fiane, Bent ^g   Van Ghelue, Marijke ^h   Clark, Neal ^a   Møller, Pål ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PELVIS CANCER; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PEDIGREE; RISK FACTOR; TUMOR SUPPRESSOR GENE;

DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; OVARIAN NEOPLASMS; PEDIGREE; RISK FACTORS;

EID: 58149347689     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0112     Document Type: Article

References (23)

1. Dorum A, Heimdal K, Lovslett K, et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 1999;78:906-11.
2. Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, Collins WP. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003;21:378-85.
3. Stirling D, Evans DG, Pichert G, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 2005;23:5588-96.
4. Møller P, Hagen AI, Apold J, et al. Genetic epidemiology of BRCA mutation - family history identifies less than 50% of mutation carriers. Eur JCancer 2007;43:1713-7.
5. Møller P, Heimdal K, Apold J, et al. Genetic epidemiology of BRCA1 mutations in Norway. Eur J Cancer 2001;37:2428-34.
6. Møller P, Borg A, Heimdal, et al. The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series. Eur J Cancer 2001;37:1027-32.
7. Stormorken AT, Bowitz-Lothe IM, Noren T, et al. Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary non-polyposis colorectal cancer. J Clin Oncol 2005;23:4705-12.
8. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22:315-27.
9. Gaarenstroom KN, van der Hiel B, Tollenaar RA, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006;16:54-9.
10. Olivier RI, Lubsen-Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006;100:20-6.
11. Bast RC, Jr., Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007;174:91-100.
12. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;20:4222-7.
13. Beiner ME, Finch A, Rosen B, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10.
14. Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001;80:395-8.
15. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2003;7:2473-81.
16. Heimdal K, Maehle L, Apold J, Pedersen JC, Moller P. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. Eur J Cancer 2003;39:2205-13.
17. Vasen HFA, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers. A study of 138 HNPCC families. J Clin Oncol 2001;19:4074-80.
18. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:85-92.
19. Singer G, Kurman RJ, Chang HW, Cho SK, Shih IeM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002;160:1223-8.
20. Moller P, Evans DG, Reis MM, et al. Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int J Cancer 2007;121:1017-20.
21. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-9.
22. Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000;18:1980-95.
23. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000;283:617-24.